Biologic versus synthetic meshes in irradiated implant-based breast reconstruction: A systematic review and meta-analysis.

J Plast Reconstr Aesthet SurgJul 3, 2026 (epub)
Clinical ResearchPlastic SurgeryOncology (Medical)

Dora L Fedorcsak, Levente Doleviczenyi, Lorinc Frivaldszky et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the outcomes of biologic versus synthetic meshes in irradiated patients undergoing implant-based breast reconstruction (IBBR). The study included 51 studies and found that the pooled complication rate was 33% for biologic mesh and 30% for synthetic mesh, with no significant difference between the two types.

Key findings

  • The pooled complication rate was 33% for biologic mesh and 30% for synthetic mesh, with no significant difference.
  • Subpectoral placement was associated with higher odds of implant loss (OR = 2.32) and capsular contracture (OR = 2.91).
  • Preoperative radiotherapy increased the odds of implant loss (OR 1.89).
  • Mesh type did not significantly affect rates of capsular contracture, implant loss, seroma, or necrosis.

Why it matters

Understanding the comparative safety of biologic and synthetic meshes in irradiated IBBR is crucial for optimizing patient outcomes and guiding clinical decision-making in breast reconstruction.

Source

PubMed · PMID 42456528

Published in J Plast Reconstr Aesthet Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.